Foundations, promises and uncertainties of personalized medicine.
暂无分享,去创建一个
[1] Urs A. Meyer,et al. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.
[2] R. Weinshilboum. Inheritance and drug response. , 2003, The New England journal of medicine.
[3] M. Campiglio,et al. Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.
[4] Geoffrey B. Nilsen,et al. Whole-Genome Patterns of Common DNA Variation in Three Human Populations , 2005, Science.
[5] Kathryn A. Phillips,et al. Measuring the value of pharmacogenomics , 2005, Nature Reviews Drug Discovery.
[6] R. Weinshilboum,et al. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions , 2006, Oncogene.
[7] D. McHale,et al. Pharmacogenomics and the Drug Discovery Pipeline , 2005 .
[8] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Rongwei Fu,et al. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force , 2005, Annals of Internal Medicine.
[10] Toshihiro Tanaka. The International HapMap Project , 2003, Nature.
[11] Gary H Lyman,et al. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. , 2005, The American journal of managed care.
[12] Gudmundur A. Thorisson,et al. The International HapMap Project Web site. , 2005, Genome research.
[13] M. McCarthy,et al. An evaluation of HapMap sample size and tagging SNP performance in large-scale empirical and simulated data sets , 2005, Nature Genetics.
[14] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[15] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[16] Julie A. Johnson,et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. , 2005, Pharmacogenetics and genomics.
[17] Randall Pruim,et al. Tag SNP selection for Finnish individuals based on the CEPH Utah HapMap database , 2006, Genetic epidemiology.
[18] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[19] E. Lander,et al. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results , 1995, Nature Genetics.
[20] P. Donnelly,et al. The effects of human population structure on large genetic association studies , 2004, Nature Genetics.
[21] K. Adams,et al. β‐adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure , 2005, Clinical pharmacology and therapeutics.
[22] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[23] N. Risch,et al. The importance of race and ethnic background in biomedical research and clinical practice. , 2003, The New England journal of medicine.
[24] R. Millikan,et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. , 2005, Journal of the National Cancer Institute.
[25] Elad Ziv,et al. Human population structure and genetic association studies. , 2003, Pharmacogenomics.